New monthly shot could simplify mental health treatment

NCT ID NCT07185815

Recruiting now Disease control Sponsor: Mapi Pharma Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 25 times

Summary

This study tests a long-acting injection of cariprazine given once a month under the skin. It is for people with schizophrenia, bipolar I disorder, or major depressive disorder who are stable on other medications. The goal is to see if the injection is safe, tolerable, and effective, potentially offering a more convenient option than daily pills.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mapi Pharma Investigational Site IL-001
RECRUITING

Tel Aviv, 6423906, Israel

Contact
Mapi Pharma Investigational Site IL-003
RECRUITING

Ness Ziona, 741000, Israel

Contact
Mapi Pharma Investigational Site IL-004
RECRUITING

Beersheba, 8461144, Israel

Contact
Mapi Pharma Investigational Site IL-005
RECRUITING

Ramat Gan, 56621, Israel

Contact
Mapi Pharma Investigational Site IN-101
RECRUITING

Ahmedabad, 380008, India

Contact
Mapi Pharma Investigational Site IN-102
RECRUITING

Ahmedabad, 380016, India

Contact

Conditions

Explore the condition pages connected to this study.

BIPOLAR 1 DISORDER BIPOLAR I DISORDER MAJOR DEPRESSIVE DISORDER MAJOR DEPRESSIVE DISORDER (MDD) SCHIZOPHRENIA